Lupin announced that its US subsidiary, Lupin has acquired Symbiomix Therapeutics. Lupin had entered into an option to acquire the company earlier this year.
The US arm of Mumbai’s Lupin Pharmaceuticals has announced that it is has acquired US-based gynaecologic treatment specialist Symbiomix Therapeutics for $150 million in a move to double down on its offerings in the women’s health market.